TVM-CAPITAL-HEALTHCARE
28.5.2024 10:02:31 CEST | Business Wire | Press release
TVM Capital Healthcare, an international healthcare expansion and growth capital investor, today announced the closing of the TVM Healthcare Afiyah Fund LP at approximately USD 250 million, its second pool of capital in the Middle East.
TVM Capital Healthcare has operated in the Middle East since 2009 and Southeast Asia since 2021. The new fund builds on the firm’s past success investing in the region, providing highly attractive returns and demonstrating its ability to originate deals and develop successful, sustainable companies with excellent growth prospects and strong management teams.
TVM Capital Healthcare identifies unmet healthcare needs and invests in entrepreneurial companies that create lasting impact in their local communities while delivering strong returns to investors. The firm has built a solid reputation as the first international fund manager investing in and operating major healthcare companies in the Kingdom. It also invests in healthcare growth deals in Europe and the U.S. to support these companies’ expansion plans for Saudi Arabia and the wider GCC. With this two-pronged, highly catalytic strategy, TVM Capital Healthcare optimizes its contribution to transforming the Saudi economy and improves access to world-leading products, technologies, and services in the region.
Among the first investments of the fund are:
- Baraya Extended Care, a Riyadh-based chain of long-term, post-acute care and rehabilitation clinics
- DEBx Medical, an Amsterdam-based developer and manufacturer of ground-breaking products for the treatment of chronic wounds that is about to enter the Saudi market
- neurocare Group, a Munich-based leading innovator in personalized mental health services and products, with clinics in the U.S., the Netherlands, and Australia, that is preparing to enter Saudi and the GCC
Other deals include longevity and genomics, oncology, pharma manufacturing, and diagnostics.
Bandr Alhomaly, Managing Director and CEO of Jada Fund of Funds, said, “The closing of TVM Healthcare Afiyah Fund marks an important milestone in mobilizing private capital into Saudi Arabia's healthcare sector, and we are pleased to lead the investment, providing capital to support the development of the sector in line with Vision 2030."
Dr. Helmut M. Schuehsler, Chairman and CEO of TVM Capital Healthcare added: “We are proud of attracting a distinguished group of institutional and family investment groups from Saudi, other GCC countries, and Europe for a specialist pool of capital of this size being deployed in domestic companies in the Kingdom and international companies entering the market. We are uniquely positioned for success because our leadership team comprises executives with long-standing expertise in Europe and the U.S., who have built excellent international networks throughout their careers, alongside local Saudi healthcare experts. Plus, we have been investing in the GCC and Egypt for over 13 years, and more specifically, operating in Saudi since 2015 through our former portfolio companies, ProVita International Medical Center and Cambridge International Medical Center. Today, we are truly excited about our ability to enhance the local and regional healthcare ecosystem at a much larger scale, helping to improve access to high-quality patient care, medical products, and treatment regimens across the Kingdom.”
TVM Capital Healthcare has offices in Riyadh, Dubai, Singapore and Ho Chi Minh City and supporting offices in Munich and Boston. It was represented in the fundraise by multinational law firm Morgan Lewis.
About TVM Capital Healthcare
TVM Capital Healthcare is an emerging markets-focused healthcare private equity firm headquartered in Dubai and Singapore, with offices in Riyadh and Ho Chi Minh City and supporting offices in Munich and Boston. The firm invests expansion and growth capital in healthcare companies to improve local access to quality care and provide local sources of medical products in the pharma, medical device and diagnostics sectors. Investment and operating partners, as well as a strong group of regional and international senior advisors have long-standing international track records in healthcare investing, active board work, contributions to strategy development and implementation, as well as deep healthcare operating experience in the relevant markets. The firm partners with local Middle Eastern and Southeast Asian management teams to build domestic or regional sector champions and selectively backs companies from Europe or North America for expansion into the firm’s target geographies.
Medical quality of its service businesses is safeguarded by collaborations with leading international medical technology and clinical partners as well as international accreditation agencies such as Joint Commission International (JCI). TVM Capital Healthcare’s investment and operating approach combines strong commercial value creation and financial returns with responsible investing in alignment with the United Nations Sustainable Development Goals (UN SDGs).
www.tvmcapitalhealthcare.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528286443/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release
ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer
Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 14:39:00 CET | Press release
Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population
Adyen Merchants Can Now Offer Klarna in AI Agent Checkout20.11.2026 14:30:00 CET | Press release
Klarna is Adyen’s first non-card, local payment method for agentic commerce Klarna (NYSE: KLAR), the everyday finance network, and Adyen (AMS: ADYEN) today announced that shoppers can now pay with Klarna when an AI agent checks out for them through Adyen Agentic. Klarna is the first payment option beyond cards available in Adyen Agentic, Adyen’s agentic commerce suite, and merchants that already offer Klarna through Adyen can switch it on with no new integration work. Today, most AI shopping agents complete purchases with a stored credit or debit card, leaving out flexible payment options that many shoppers choose at regular checkout. With Klarna now a payment method within Adyen Agentic, the agent shows shoppers the same Klarna options the merchant already offers, such as paying in full, in interest-free installments or with financing. Shoppers review and confirm every purchase before it is completed. Adyen built the integration on Klarna’s open payment handler, a published specificat
SatSure Raises Series B to Scale Its Full-Stack Earth Intelligence Platform for Global Markets20.11.2026 11:05:00 CET | Press release
India’s sovereign space-technology fund leads the first close of the ongoing INR 200 crore (c. USD 21 million) round SatSure, a global Earth intelligence company headquartered in India, today announced the first close of its ongoing INR 200 crore (c. USD 21 million) Series B round. The round is led by a INR 60 crore (c. USD 6.4 million) investment from the Antariksh Venture Capital Fund (AVCF), India’s sovereign space-technology fund, anchored by the national space regulator IN-SPACe and managed by SIDBI Venture Capital Limited. The investment marks AVCF’s first deployment into the downstream data and AI layer of India’s space economy, extending the fund beyond upstream launch and satellite hardware into commercial space-data infrastructure capable of serving global enterprise and sovereign markets. The round comprises INR 165 crore (c. USD 17.6 million) in equity, INR 25 crore (c. USD 2.7 million) in venture debt and INR 10 crore (c. USD 1.1 million) in secondary transactions, closing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
